AVDL Avadel Pharmaceuticals plc

2.74
-0.02  -1%
Previous Close 2.76
Open 2.75
Price To Book -10.54
Market Cap 102,354,100
Shares 37,355,511
Volume 207,472
Short Ratio
Av. Daily Volume 371,066

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
Announced approval May 2 2016
Akovaz
Hypotension
Phase 3 enrolment to be completed 2H 2020.
FT 218
Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy
Approved June 30 2014.
VAZCULEP (phenylephrine hydrochloride)
Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia
Approved Jun 3 2013
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
PDUFA date September 15, 2019.
AV001
Hospital product

Latest News

  1. Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
  2. Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference
  3. Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer
  4. Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001
  5. Introducing Avadel Pharmaceuticals (NASDAQ:AVDL), The Stock That Tanked 82%
  6. Avadel: 1Q Earnings Snapshot
  7. Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results
  8. Avadel Pharmaceuticals Plc to Host Earnings Call
  9. Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results
  10. Avadel Pharmaceuticals Announces Appointment of Jordan Dubow, M.D., as Chief Medical Officer
  11. Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
  12. Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
  13. Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  14. Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
  15. Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring
  16. Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program
  17. ‘Sleep Normal’ campaign urges Americans to end frequent nighttime urination and stop settling for nights of bad sleep
  18. Read This Before Selling Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares